Matches in Wikidata for { <http://www.wikidata.org/entity/Q60473065> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- Q60473065 description "article scientifique publié en 2015" @default.
- Q60473065 description "article" @default.
- Q60473065 description "im September 2015 veröffentlichter wissenschaftlicher Artikel" @default.
- Q60473065 description "wetenschappelijk artikel" @default.
- Q60473065 description "наукова стаття, опублікована у вересні 2015" @default.
- Q60473065 description "հոդված" @default.
- Q60473065 name "3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience" @default.
- Q60473065 name "3062 Ceritinib following crizotinib in ALK-positive" @default.
- Q60473065 type Item @default.
- Q60473065 label "3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience" @default.
- Q60473065 label "3062 Ceritinib following crizotinib in ALK-positive" @default.
- Q60473065 prefLabel "3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience" @default.
- Q60473065 prefLabel "3062 Ceritinib following crizotinib in ALK-positive" @default.
- Q60473065 P1433 Q60473065-D8C133D9-7771-447F-83C0-1D573FBE0645 @default.
- Q60473065 P1476 Q60473065-D912D99C-1B73-48A1-905A-6A9E0E1228D5 @default.
- Q60473065 P2093 Q60473065-04FA0419-F653-405F-B1EB-1FA181A775B9 @default.
- Q60473065 P2093 Q60473065-27F1B852-4B7A-4468-BD11-BFB0C01CDDF3 @default.
- Q60473065 P2093 Q60473065-2EA9FF57-42EC-4193-810E-C4957EBC633A @default.
- Q60473065 P2093 Q60473065-2FA5A237-33B2-4E7F-8D49-E847305C9DB9 @default.
- Q60473065 P2093 Q60473065-5AB2D490-2C27-466A-9602-5CF567DABF08 @default.
- Q60473065 P2093 Q60473065-5D24495F-AC5B-4833-A56B-83CC5425957E @default.
- Q60473065 P2093 Q60473065-E5000624-E422-4C5B-A615-2B6A3BAD930B @default.
- Q60473065 P2093 Q60473065-F64D0F51-6357-4DBE-B49D-892E296103B3 @default.
- Q60473065 P2093 Q60473065-F6AE2750-05E0-4875-B36D-7FE5550F509E @default.
- Q60473065 P304 Q60473065-117741D0-A0C9-40B9-8818-56B5D17B97B2 @default.
- Q60473065 P31 Q60473065-BE6C673C-6710-4763-B460-94B8726A6897 @default.
- Q60473065 P356 Q60473065-45A10187-B96F-401D-812A-B3B78A3AFF7E @default.
- Q60473065 P478 Q60473065-A6255E75-A083-4B6A-AE13-F692B2D3736E @default.
- Q60473065 P50 Q60473065-7730261F-51A7-42C1-8D95-E80608C2985B @default.
- Q60473065 P577 Q60473065-C1BC958B-75FF-42D3-835C-CAEF574E77AE @default.
- Q60473065 P921 Q60473065-552E22FB-6D40-4A3E-B803-3DE2005EF1DE @default.
- Q60473065 P921 Q60473065-8BA70731-5D6E-4194-98DC-F9A61B63E116 @default.
- Q60473065 P921 Q60473065-C6253E92-2C7F-43DA-A965-48681EC114EC @default.
- Q60473065 P356 S0959-8049(16)31704-X @default.
- Q60473065 P1433 Q332260 @default.
- Q60473065 P1476 "3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience" @default.
- Q60473065 P2093 "A. Cortot" @default.
- Q60473065 P2093 "B. Mennecier" @default.
- Q60473065 P2093 "E. Dansin" @default.
- Q60473065 P2093 "F. Barlesi" @default.
- Q60473065 P2093 "H. Lena" @default.
- Q60473065 P2093 "J. Cadranel" @default.
- Q60473065 P2093 "J. Mazieres" @default.
- Q60473065 P2093 "M. Perol" @default.
- Q60473065 P2093 "P. Do" @default.
- Q60473065 P304 "S616-S617" @default.
- Q60473065 P31 Q13442814 @default.
- Q60473065 P356 "10.1016/S0959-8049(16)31704-X" @default.
- Q60473065 P478 "51" @default.
- Q60473065 P50 Q57027992 @default.
- Q60473065 P577 "2015-09-01T00:00:00Z" @default.
- Q60473065 P921 Q21011233 @default.
- Q60473065 P921 Q3658562 @default.
- Q60473065 P921 Q5186964 @default.